Aspirin Use to Prevent Cardiovascular Disease
Authors:
- Us Preventive Services Task ForceUFUs Preventive Services Task Force
Open Access
- 26 April 2022
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (16) , 1577-1584
Abstract
See the Summary of Recommendations figure.Keywords
This publication has 29 references indexed in Scilit:
- Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2016
- An Analysis of Calibration and Discrimination Among Multiple Cardiovascular Risk Scores in a Modern Multiethnic CohortAnnals of Internal Medicine, 2015
- Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized TrialAnnals of Internal Medicine, 2013
- Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohortsJournal of Gastroenterology, 2013
- Association of Aspirin Use With Major Bleeding in Patients With and Without DiabetesJAMA, 2012
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself?Physiological Reviews, 2008
- Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased riskThe Lancet, 1998
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989